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Atrial Arrhythmias After Cardiac
Surgery: Sisyphus Revisited?*
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The treatment of atrial arrhythmias after cardiac surgery has
been an area of keen research interest over the last several
years (1). Part of the motivation to find effective therapy is
monetary. When atrial fibrillation or flutter (AFF) occurs
postoperatively, patients remain in the hospital longer, and
that costs money (2). When one considers the fact that
cardiac surgery is the most common major surgical proce-
dure in the U.S. and that AFF may be responsible for as
much as a 30% increase in the real cost of the procedure, it
is not hard to understand the attention that this problem has
garnered (3). The arrhythmia causes symptoms, but even in
patients with left ventricular dysfunction, these are not
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usually severe. Although there is the real risk of thrombo-
embolic events in these patients, for whom anticoagulation
carries an added hazard, the jeopardy period is relatively
short, and so the amortized risk translates into a small
number of patients who actually have a stroke or major
hemorrhage (4). The risk period is brief because this is a
self-limited disease in most patients; data from our institu-
tion indicate that over 95% of patients who develop parox-
ysmal AFF de novo after cardiac surgery are in normal sinus
rhythm within two months after coronary artery bypass graft
surgery (5). Physician concern about sending symptomatic
patients home in AFF stalls the flow of patients out of the
hospital. Hospital administrators, payers, patients and fam-
ilies prefer early discharge, and so the push for better
treatment methods continues.
How does one go about treatment? Because physicians
have no clear idea as to the mechanisms that generate the
arrhythmia, treatment has been highly empiric. The most
common scenario is to try to terminate the arrhythmia after
it has occurred. There are several ways to acutely convert
AFF to sinus rhythm that are electric as well as pharmaco-
logic (6). The problem with either is a high relapse rate,
especially in patients who are very ill and have high
sympathetic tone, in whom all of the conditions for arrhyth-
mia reinitiation are present. Thus, acute measures are often
coupled with administration of oral antiarrhythmic drugs
started either before of after cardioversion. To avoid the
potential for antiarrhythmic toxicity, many clinicians have
favored the conservative approach of rate control and
anticoagulation over the term of the hospitalization, again
with the knowledge that most patients will recover sinus
rhythm spontaneously when they recuperate from surgery at
home. The problem here is akin to the nonsurgical situa-
tion: there are no worthwhile trial data whatsoever that give
a clear direction as to whether the strategy of rhythm control
or rate control strategy is superior for attainment of any
clinical end point.
Given the lack of a clear treatment directive, prophylaxis
is a highly attractive goal that has been pursued since the
inception of modern cardiac surgery. It has been learned
from early experience that calcium channel blocking agents
and digitalis are not particularly helpful, but that beta-
blockade, with or without digitalis, reduces the incidence of
the arrhythmia from about 40% for coronary surgery and
60% for valve surgery to 20% and 30%, respectively, for a
50% risk reduction (7). Still, with over 650,000 patients at
risk, prevention methods that can reduce the occurrence
even further may be worthwhile, and so the search for better
methods of prophylaxis has continued. So far we have
learned that membrane-active antiarrhythmic drugs have
some activity, but it has been difficult to quantitate their
benefit. Studies of older sodium channel blocking agents
enrolled a relatively small number of patients with diverse
clinical profiles, and the magnitude of treatment effect
varied widely from study to study, in part because not all had
applied proper background therapy (8). Careful quantifica-
tion of benefit is particularly important in this realm,
because these agents have strong potential for harm. Ven-
tricular proarrhythmia is the most feared complication and
mandates in-hospital observation during drug initiation.
Perhaps more commonly, these drugs can cause malignant
bradycardia and the need for cardiac pacing. A small
number of these patients may end their hospitalization with
a permanent cardiac pacemaker, which is not a good
outcome when treating a disease that lasts only weeks and in
many patients causes minimal symptoms.
There are several adequately designed and powered clin-
ical trials, recently completed or in progress, that will
examine the value of newer antiarrhythmic drugs for this
indication, including propafenone, sotalol and amiodarone
(9). The latter is the most intriguing candidate. Its track
record of efficacy and safety in low doses for the treatment
of AFF in other spheres is compelling (10). In addition, it
has myriad electrophysiologic effects, some of which should
be useful to control the heart rate response if AFF recurs.
The oral form of the drug, used alone, does not lend itself
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well to this indication (11). It takes too long to achieve a
satisfactory myocardial concentration of the drug. A pro-
longed period of oral loading preoperatively is necessary to
achieve a therapeutic effect, a strategy that is not feasible in
most patients, and that may expose patients to a small but
finite operative pulmonary risk (12). Enter Guarnieri et al.
(13), who reasoned appropriately that administration of the
intravenous drug immediately postoperatively might be
worthwhile. Although they proved benefit in reducing AFF
incidence without substantial risk, the magnitude of the
benefit was not large enough to translate into a reduced
length of stay. Given the high cost of intravenous therapy
($500 to $700 per day), it is not a strategy to be recom-
mended. However, the signal is clear, and protocols are
being designed to extend the period of intravenous dosing
and to couple it with oral therapy in some fashion, to
maximize the chances of attaining an adequate myocardial
concentration within two to five days after surgery, the
period of maximum arrhythmia risk.
Is there a solution, or are cardiologists and cardiac
surgeons damned to rock-rolling futility? It is unlikely that
the problem will go away. Minimally invasive surgical
techniques will not eliminate the problem; there now exists
data to prove that the incidence of AFF in these patients,
when corrected for disease severity, is the same as for those
who have conventional sternotomy (14). Physicians are
likely to see more attempts to identify drug strategies,
perhaps using accessory methods to target patients at
highest risk (15). For example, some have advocated the use
of signal averaging techniques to measure p-wave duration,
followed by more aggressive drug therapy in patients in the
highest risk categories (16). Others have explored novel
methods of drug delivery such as direct pericardial instilla-
tion, or even adding an antiarrhythmic drug to the witch’s
brew known as cardioplegia solution (17).
What of nondrug therapy? Tested in a relatively small
number of patients, single or multiple site atrial pacing has
not prevented AFF development (18). Specialists have
recently learned of the potential value of an internal defi-
brillation method in which coiled epicardial, temporary
wires, placed at the time of surgery, can be used to deliver
small amounts of current with minimal discomfort and very
good results (19). One can envision “hybrid therapy” in
which patients are treated with an oral antiarrhythmic drug
and the small number with a breakthrough episode of AFF
have their arrhythmia pace terminated (if flutter), or car-
dioverted via epicardial wires (if fibrillation) as they prepare
to leave the hospital (20).
Unfortunately, none of these novel ideas, as intriguing as
they are, have been subjected to the rigors of an adequately
controlled clinical trial. For now, what should our approach
be? I believe that beta-adrenergic blocking agents should be
used as soon as possible after surgery to maximize their
benefit. When AFF develops, there needs to be a prompt
decision about management, either rate or rhythm control,
and drugs should be instituted promptly. In informal
surveys in our hospital, stays have been prolonged in most
cases by needless delays in instituting effective therapies,
especially anticoagulation. Patients not only need excellent
and careful in-hospital management, but they also need to
be watched carefully after discharge. Policies of early dis-
missal have been associated with readmission rates ap-
proaching 40%, and half of these have been for AFF that
occurred in its usual time frame but after a short hospital
stay (21). Likewise, patients who are treated with antiar-
rhythmic drugs or anticoagulation need to be reassessed in
the two to three months after surgery for their need for
continued treatment, because the arrhythmia is likely to
remit (5).
Unlike the case of Sisyphus, the king of Corinth notori-
ous for his brigandage, condemned to Hades to have his
boulder perpetually roll back to the bottom of the hill, there
has been clear progress in the ability to help patients with
AFF after cardiac surgery. But push on (and up) we must.
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